Search

Your search keyword '"Reinthaler, Markus"' showing total 217 results
Start Over Author "Reinthaler, Markus"
217 results on '"Reinthaler, Markus"'

3. Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study

Author

Lurz, Philipp, Schmitz, Thomas, Geisler, Tobias, Hausleiter, Jörg, Eitel, Ingo, Rudolph, Volker, Lubos, Edith, von Bardeleben, Ralph Stephan, Brambilla, Nedy, De Marco, Federico, Berti, Sergio, Nef, Holger, Linke, Axel, Hengstenberg, Christian, Baldus, Stephan, Spargias, Konstantinos, Denti, Paolo, Nickenig, Georg, Möllmann, Helge, Rottbauer, Wolfgang, Praz, Fabien, Butter, Christian, Reinthaler, Markus, Van Mieghem, Nicolas M., Sherif, Mohammad, Swaans, Martin, Witkowski, Adam, Buch, Mamta, Seidler, Tim, Iñiguez, Andrés, Thiele, Holger, Eißmann, Mareike, Schreieck, Juergen, Näbauer, Michael, Marcoff, Leo, Koulogiannis, Konstantinos, Rassaf, Tienush, and Luedike, Peter

Published
2024
Full Text
View/download PDF

7. Mitral Valve Transcatheter Edge-to-Edge Repair:1-Year Outcomes From the MiCLASP Study

Author

Lurz, Philipp, Schmitz, Thomas, Geisler, Tobias, Hausleiter, Jörg, Eitel, Ingo, Rudolph, Volker, Lubos, Edith, von Bardeleben, Ralph Stephan, Brambilla, Nedy, De Marco, Federico, Berti, Sergio, Nef, Holger, Linke, Axel, Hengstenberg, Christian, Baldus, Stephan, Spargias, Konstantinos, Denti, Paolo, Nickenig, Georg, Möllmann, Helge, Rottbauer, Wolfgang, Praz, Fabien, Butter, Christian, Reinthaler, Markus, Van Mieghem, Nicolas M., Sherif, Mohammad, Swaans, Martin, Witkowski, Adam, Buch, Mamta, Seidler, Tim, Iñiguez, Andrés, Thiele, Holger, Eißmann, Mareike, Schreieck, Juergen, Näbauer, Michael, Marcoff, Leo, Koulogiannis, Konstantinos, Rassaf, Tienush, Luedike, Peter, Lurz, Philipp, Schmitz, Thomas, Geisler, Tobias, Hausleiter, Jörg, Eitel, Ingo, Rudolph, Volker, Lubos, Edith, von Bardeleben, Ralph Stephan, Brambilla, Nedy, De Marco, Federico, Berti, Sergio, Nef, Holger, Linke, Axel, Hengstenberg, Christian, Baldus, Stephan, Spargias, Konstantinos, Denti, Paolo, Nickenig, Georg, Möllmann, Helge, Rottbauer, Wolfgang, Praz, Fabien, Butter, Christian, Reinthaler, Markus, Van Mieghem, Nicolas M., Sherif, Mohammad, Swaans, Martin, Witkowski, Adam, Buch, Mamta, Seidler, Tim, Iñiguez, Andrés, Thiele, Holger, Eißmann, Mareike, Schreieck, Juergen, Näbauer, Michael, Marcoff, Leo, Koulogiannis, Konstantinos, Rassaf, Tienush, and Luedike, Peter

Abstract

Background: Mitral transcatheter edge-to-edge repair (M-TEER) is a guideline-recommended treatment option for patients with severe symptomatic mitral regurgitation (MR). Outcomes with the PASCAL system in a post-market setting have not been established. Objectives: The authors report 30-day and 1-year outcomes from the MiCLASP (Transcatheter Repair of Mitral Regurgitation with Edwards PASCAL Transcatheter Valve Repair System) European post-market clinical follow-up study. Methods: Patients with symptomatic, clinically significant MR were prospectively enrolled. The primary safety endpoint was clinical events committee–adjudicated 30-day composite major adverse event rate and the primary effectiveness endpoint was echocardiographic core laboratory–assessed MR severity at discharge compared with baseline. Clinical, echocardiographic, functional, and quality-of-life outcomes were assessed at 1 year. Results: A total of 544 patients were enrolled (59% functional MR, 30% degenerative MR). The 30-day composite major adverse event rate was 6.8%. MR reduction was significant from baseline to discharge and sustained at 1 year with 98% of patients achieving MR ≤2+ and 82.6% MR ≤1+ (all P < 0.001 vs baseline). One-year Kaplan-Meier estimate for survival was 87.3%, and freedom from heart failure hospitalization was 84.3%. Significant functional and quality-of-life improvements were observed at 1 year, including 71.6% in NYHA functional class I/II, 14.4-point increase in Kansas City Cardiomyopathy Questionnaire score, and 24.2-m improvement in 6-minute walk distance (all P < 0.001 vs baseline). Conclusions: One-year outcomes of this large cohort from the MiCLASP study demonstrate continued safety and effectiveness of M-TEER with the PASCAL system in a post-market setting. Results demonstrate high survival and freedom from heart failure hospitalization, significant and sustained MR reduction, and improvements in symptoms, functional capacity, and quality of life.

Published
2024

9. Impact of route of access and stenosis subtype on outcome after transcatheter aortic valve replacement

Author

Maier, Julian, primary, Lambert, Thomas, additional, Senoner, Thomas, additional, Dobner, Stephan, additional, Hoppe, Uta Caroline, additional, Fellner, Alexander, additional, Pfeifer, Bernhard Erich, additional, Feuchtner, Gudrun Maria, additional, Friedrich, Guy, additional, Semsroth, Severin, additional, Bonaros, Nikolaos, additional, Holfeld, Johannes, additional, Müller, Silvana, additional, Reinthaler, Markus, additional, Steinwender, Clemens, additional, and Barbieri, Fabian, additional

Published
2023
Full Text
View/download PDF

15. Left-ventricular unloading in extracorporeal cardiopulmonary resuscitation due to acute myocardial infarction – A multicenter study

Author

Thevathasan, Tharusan, primary, Kenny, Megan A., additional, Krause, Finn J., additional, Paul, Julia, additional, Wurster, Thomas, additional, Boie, Sebastian D., additional, Friebel, Julian, additional, Knie, Wulf, additional, Girke, Georg, additional, Haghikia, Arash, additional, Reinthaler, Markus, additional, Rauch-Kröhnert, Ursula, additional, Leistner, David M., additional, Sinning, David, additional, Fröhlich, Georg, additional, Heidecker, Bettina, additional, Spillmann, Frank, additional, Praeger, Damaris, additional, Pieske, Burkert, additional, Stangl, Karl, additional, Landmesser, Ulf, additional, Balzer, Felix, additional, and Skurk, Carsten, additional

Published
2023
Full Text
View/download PDF

17. New Cerebral Microbleeds After Catheter‐Based Structural Heart Interventions: An Exploratory Analysis

Author

Braemswig, Tim Bastian, primary, Kusserow, Madeleine, additional, Bellmann, Barbara, additional, Beckhoff, Frederik, additional, Reinthaler, Markus, additional, von Rennenberg, Regina, additional, Erdur, Hebun, additional, Scheitz, Jan F., additional, Galinovic, Ivana, additional, Villringer, Kersten, additional, Leistner, David M., additional, Audebert, Heinrich J., additional, Endres, Matthias, additional, Landmesser, Ulf, additional, Haeusler, Karl Georg, additional, Fiebach, Jochen B., additional, Lauten, Alexander, additional, Rillig, Andreas, additional, and Nolte, Christian H., additional

Published
2023
Full Text
View/download PDF

22. Safety and Healthcare Resource Utilization in Patients Undergoing Left Atrial Appendage Closure—A Nationwide Analysis.

Author

Thevathasan, Tharusan, Degbeon, Sêhnou, Paul, Julia, Wendelburg, Darius-Konstantin, Füreder, Lisa, Gaul, Anna Leonie, Scheitz, Jan F., Stadler, Gertraud, Rroku, Andi, Lech, Sonia, Buspavanich, Pichit, Huemer, Martin, Attanasio, Philipp, Nagel, Patrick, Reinthaler, Markus, Landmesser, Ulf, and Skurk, Carsten

Subjects
LEFT heart atrium, PATIENTS, MEDICAL care, POISSON regression, ATRIAL fibrillation
Abstract

Percutaneous left atrial appendage closure (LAAC) has emerged as a non-pharmacological alternative for stroke prevention in patients with atrial fibrillation (AF) not suitable for anticoagulation therapy. Real-world data on peri-procedural outcomes are limited. The aim of this study was to analyze outcomes of peri-procedural safety and healthcare resource utilization in 11,240 adult patients undergoing LAAC in the United States between 2016 and 2019. Primary outcomes (safety) were in-hospital ischemic stroke or systemic embolism (SE), pericardial effusion (PE), major bleeding, device embolization and mortality. Secondary outcomes (resource utilization) were adverse discharge disposition, hospital length of stay (LOS) and costs. Logistic and Poisson regression models were used to analyze outcomes by adjusting for 10 confounders. SE decreased by 97% between 2016 and 2019 [95% Confidence Interval (CI) 0–0.24] (p = 0.003), while a trend to lower numbers of other peri-procedural complications was determined. In-hospital mortality (0.14%) remained stable. Hospital LOS decreased by 17% (0.78–0.87, p < 0.001) and adverse discharge rate by 41% (95% CI 0.41–0.86, p = 0.005) between 2016 and 2019, while hospital costs did not significantly change (p = 0.2). Female patients had a higher risk of PE (OR 2.86 [95% CI 2.41–6.39]) and SE (OR 5.0 [95% CI 1.28–43.6]) while multi-morbid patients had higher risks of major bleeding (p < 0.001) and mortality (p = 0.031), longer hospital LOS (p < 0.001) and increased treatment costs (p = 0.073). Significant differences in all outcomes were observed between male and female patients across US regions. In conclusion, LAAC has become a safer and more efficient procedure. Significant sex differences existed across US regions. Careful considerations should be taken when performing LAAC in female and comorbid patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs

Author

Silbernagel, Günther, primary, Scharnagl, Hubert, additional, Saely, Christoph H., additional, Reinthaler, Markus, additional, Rief, Martin, additional, Kleber, Marcus E., additional, Larcher, Barbara, additional, Chapman, John, additional, Schaefer, Juergen R., additional, Drexel, Heinz, additional, and März, Winfried, additional

Published
2022
Full Text
View/download PDF

25. Cerebral embolisation during transcatheter edge-to-edge repair of the mitral valve with the MitraClip system: a prospective, observational study

Author

Braemswig, Tim Braemswig, primary, Kusserow, Madeleine Kusserow, additional, Kruppa, Jochen, additional, Reinthaler, Markus, additional, Erdur, Hebun, additional, Fritsch, Merve, additional, Curio, Jonathan, additional, Alushi, Brunilda, additional, Villringer, Kersten, additional, Galinovic, Ivana, additional, Berger, Christian, additional, Leistner, David Leistner, additional, Audebert, Heinrich Audebert, additional, Endres, Matthias, additional, Landmesser, Ulf, additional, Fiebach, Jochen Fiebach, additional, Nolte, Christian Nolte, additional, Beckhoff, Frederik, additional, and Lauten, Alexander, additional

Published
2022
Full Text
View/download PDF

26. Olive Oil

Author

Silbernagel, Günther, primary, Bigalke, Boris, additional, Kasner, Mario, additional, and Reinthaler, Markus, additional

Published
2022
Full Text
View/download PDF

30. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study: The TriBAND study 30-day outcomes

Author

Nickenig, Georg, Friedrichs, Kai, Baldus, Stephan, Arnold, Martin, Seidler, Tim, Hakmi, Samer, Linke, Axel, Schäfer, Ulrich, Dreger, Henryk, Reinthaler, Markus, von Bardeleben, Ralph, Möllmann, Helge, Weber, Marcel, Roder, Fabian, Körber, Maria, Landendinger, Melanie, Wolf, Frieder, Alessandrini, Hannes, Sveric, Krunoslav, Schewel, Dimitry, Romero-Dorta, Elena, Kasner, Mario, Dahou, Abdellaziz, Hahn, Rebecca T., and Windecker, Stephan

Subjects
Heart Valve Prosthesis Implantation, Cardiac Catheterization, Time Factors, Treatment Outcome, Clinical Research, Quality of Life, Humans, Prospective Studies, Severity of Illness Index, Tricuspid Valve Insufficiency, Follow-Up Studies
Abstract

BACKGROUND: Severe tricuspid regurgitation (TR) has limited treatment options and is associated with high morbidity and mortality. AIMS: We evaluated the safety and effectiveness of the Cardioband tricuspid valve reconstruction system from the ongoing European single-arm, multicentre, prospective TriBAND post-market clinical follow-up study. METHODS: Eligible patients had chronic symptomatic functional TR despite diuretic therapy and were deemed candidates for transcatheter tricuspid repair by the local Heart Team. RESULTS: Sixty-one patients had ≥severe functional TR. At baseline, 85% of patients were in NYHA Class III-IV, 94% had ≥severe TR (core laboratory-assessed) with 6.8% EuroSCORE II and 53% LVEF. Device success was 96.7%. At discharge, 59% (p

Published
2021

34. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study

Author

Nickenig, Georg, primary, Friedrichs, Kai P., additional, Baldus, Stephan, additional, Arnold, Martin, additional, Seidler, Tim, additional, Hakmi, Samer, additional, Linke, Axel, additional, Schäfer, Ulrich, additional, Dreger, Henryk, additional, Reinthaler, Markus, additional, von Bardeleben, Ralph Stephan, additional, Möllmann, Helge, additional, Weber, Marcel, additional, Roder, Fabian, additional, Körber, Maria Isabel, additional, Landendinger, Melanie, additional, Wolf, Frieder, additional, Alessandrini, Hannes, additional, Sveric, Krunoslav, additional, Schewel, Dimitry, additional, Romero-Dorta, Elena, additional, Kasner, Mario, additional, Dahou, Abdellaziz, additional, Hahn, Rebecca T., additional, and Windecker, Stephan, additional

Published
2021
Full Text
View/download PDF

35. TCT-140 A Novel Device for TR Reduction With a Feature of “3D Leaflet” Hanging in the Center of the Tricuspid Valve With an Atraumatic Anchoring Mechanism: The Pivot-TR System

Author

Seung-Whan, Lee, primary, Lee, Pil Hyung, additional, Kim, Dae-Hee, additional, Kim, Tae Oh, additional, Yang, Dong Hyun, additional, Koo, Huunjung, additional, Chon, Min-Ku, additional, Park, Yong-Hyun, additional, Reinthaler, Markus, additional, Park, Jai-Wun, additional, Barbieri, Fabian, additional, and Kim, June Hong, additional

Published
2021
Full Text
View/download PDF

36. Coronary Artery Dimensions in Endurance Athletes by Computed Tomography Angiography: A Quantitative Analysis

Author

Langer, Christian, primary, Barbieri, Fabian, additional, Plank, Fabian, additional, Beyer, Christoph, additional, Baldauf, Benito, additional, Friedrich, Guy, additional, Widmann, Gerlig, additional, Luger, Anna, additional, Adukauskaite, Agne, additional, Reinthaler, Markus, additional, Dichtl, Wolfgang, additional, Homma, Shunichi, additional, and Feuchtner, Gudrun Maria, additional

Published
2021
Full Text
View/download PDF

40. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study

Author

Nickenig, Georg, Friedrichs, Kai P., Baldus, Stephan, Arnold, Martin, Seidler, Tim, Hakmi, Samer, Linke, Axel, Schaefer, Ulrich, Dreger, Henryk, Reinthaler, Markus, von Bardeleben, Ralph Stephan, Moellmann, Helge, Weber, Marcel, Roder, Fabian, Koerber, Maria Isabel, Landendinger, Melanie, Wolf, Frieder, Alessandrini, Hannes, Sveric, Krunoslav, Schewel, Dimitry, Romero-Dorta, Elena, Kasner, Mario, Dahou, Abdellaziz, Hahn, Rebecca T., Windecker, Stephan, Nickenig, Georg, Friedrichs, Kai P., Baldus, Stephan, Arnold, Martin, Seidler, Tim, Hakmi, Samer, Linke, Axel, Schaefer, Ulrich, Dreger, Henryk, Reinthaler, Markus, von Bardeleben, Ralph Stephan, Moellmann, Helge, Weber, Marcel, Roder, Fabian, Koerber, Maria Isabel, Landendinger, Melanie, Wolf, Frieder, Alessandrini, Hannes, Sveric, Krunoslav, Schewel, Dimitry, Romero-Dorta, Elena, Kasner, Mario, Dahou, Abdellaziz, Hahn, Rebecca T., and Windecker, Stephan

Abstract

Background: Severe tricuspid regurgitation (TR) has limited treatment options and is associated with high morbidity and mortality. Aims: We evaluated the safety and effectiveness of the Cardioband tricuspid valve reconstruction system from the ongoing European single-arm, multicentre, prospective TriBAND post-market clinical follow-up study. Methods: Eligible patients had chronic symptomatic functional TR despite diuretic therapy and were deemed candidates for transcatheter tricuspid repair by the local Heart Team. Results: Sixty-one patients had >= severe functional TR. At baseline, 85% of patients were in NYHA Class III-IV, 94% had ?severe TR (core laboratory-assessed) with 6.8% EuroSCORE II and 53% LVEF. Device success was 96.7%. At discharge, 59% (p<0.001) of patients achieved <= moderate TR and 78% had at least one grade TR reduction. At 30 days, all-cause mortality and composite MAE rates were 1.6% and 19.7%, respectively; septolateral annular diameter was reduced by 20%, where 69% of patients achieved <= moderate TR and 85% of patients had at least one grade TR reduction (all p<0.001). Mid-RVEDD, RA volume, and IVC diameter decreased by 10% (p=0.005), 21% (p<0.001), and 11% (p=0.022), respectively; 74% were in NYHA Class I-II (p<0.001) with improvements in overall KCCQ score by 17 points (p<0.001). Conclusions: In the TriBAND study, the Cardioband tricuspid system demonstrated favourable outcomes at discharge and 30 days in a challenging patient population with symptomatic ?severe functional TR. Results showed significant reductions in annular diameter and TR severity, accompanied by early evidence of right heart remodelling and improvements in functional status and quality of life.

Published
2021

43. In Vitro Thrombogenicity Testing of Biomaterials

Author

Braune, Steffen (Dr.), Latour, Robert A., Reinthaler, Markus, Landmesser, Ulf, Lendlein, Andreas, and Jung, Friedrich

Subjects
ddc:570, Institut für Chemie
Abstract

The short- and long-term thrombogenicity of implant materials is still unpredictable, which is a significant challenge for the treatment of cardiovascular diseases. A knowledge-based approach for implementing biofunctions in materials requires a detailed understanding of the medical device in the biological system. In particular, the interplay between material and blood components/cells as well as standardized and commonly acknowledged in vitro test methods allowing a reproducible categorization of the material thrombogenicity requires further attention. Here, the status of in vitro thrombogenicity testing methods for biomaterials is reviewed, particularly taking in view the preparation of test materials and references, the selection and characterization of donors and blood samples, the prerequisites for reproducible approaches and applied test systems. Recent joint approaches in finding common standards for a reproducible testing are summarized and perspectives for a more disease oriented in vitro thrombogenicity testing are discussed.

Published
2019

47. Pulmonary hypertension in patients with severe aortic stenosis: prognostic impact after transcatheter aortic valve replacement: pulmonary hypertension in patients undergoing TAVR

Author

Alushi, Brunilda, Beckhoff, Frederik, Leistner, David, Franz, Marcus, Reinthaler, Markus, Stähli, Barbara E, Morguet, Andreas, Figulla, Hans R, Doenst, Torsten, Maisano, Francesco, Falk, Volkmar, Landmesser, Ulf, Lauten, Alexander, University of Zurich, and Lauten, Alexander

Subjects
aortic Stenosis, dysfunction, 10209 Clinic for Cardiology, 2741 Radiology, Nuclear Medicine and Imaging, 610 Medicine & health, pulmonary Hypertension, TAVR, right ventricular, aortic valve, tricuspid regurgitation, 2705 Cardiology and Cardiovascular Medicine, 10020 Clinic for Cardiac Surgery
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results